Antimicrobial Agents — MCQs

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 971: A patient with febrile neutropenia has a blood culture that grew Pseudomonas aeruginosa. The isolate was found to be a producer of extended-spectrum beta-lactamase (ESBL) enzyme. What is the most appropriate antimicrobial therapy?

A. Ceftazidime + amikacin
B. Aztreonam + amikacin
C. Cefpirome + amikacin
D. Imipenem + amikacin (Correct Answer)

Explanation: ### Explanation The correct answer is **D. Imipenem + amikacin.** **1. Why Imipenem + amikacin is correct:** The patient has a **Pseudomonas aeruginosa** infection that produces **Extended-Spectrum Beta-Lactamase (ESBL)**. ESBL enzymes hydrolyze most penicillins, cephalosporins (including 3rd and 4th generations), and monobactams. **Carbapenems** (like Imipenem or Meropenem) are the drugs of choice for ESBL-producing organisms because they are highly resistant to hydrolysis by these enzymes. In febrile neutropenia, guidelines recommend combining a potent anti-pseudonal beta-lactam with an **Aminoglycoside** (like Amikacin) for synergistic effect and to prevent the emergence of resistance. **2. Why other options are incorrect:** * **A & C (Ceftazidime/Cefpirome):** While Ceftazidime (3rd gen) and Cefpirome (4th gen) have anti-pseudomonal activity, they are inactivated by ESBL enzymes. Using them against an ESBL producer would lead to treatment failure. * **B (Aztreonam):** Aztreonam is a monobactam. Like cephalosporins, it is susceptible to degradation by ESBLs. It is typically reserved for patients with a severe penicillin allergy but is ineffective here. **3. High-Yield Clinical Pearls for NEET-PG:** * **ESBL Definition:** Enzymes that confer resistance to all 1st, 2nd, and 3rd generation cephalosporins and monobactams. * **Drug of Choice for ESBL:** Carbapenems (Imipenem, Meropenem, Ertapenem). * **Pseudomonas Coverage:** Not all carbapenems cover Pseudomonas; **Ertapenem** is the notable exception (it lacks activity against *P. aeruginosa*). * **Febrile Neutropenia:** Defined as a single oral temperature of $>38.3^\circ\text{C}$ or $>38.0^\circ\text{C}$ for 1 hour, with an Absolute Neutrophil Count (ANC) $<500$ cells/$\text{mm}^3$. Empiric therapy must always cover *Pseudomonas*.

Question 972: Moxidectin was approved by FDA recently for which condition?

A. Filariasis
B. Onchocerca volvulus (Correct Answer)
C. Hypertension
D. Scabies

Explanation: **Explanation:** **Moxidectin** is a potent second-generation macrocyclic lactone (derived from milbemycin) that was FDA-approved in 2018 for the treatment of **Onchocerciasis (River Blindness)** in patients aged 12 years and older. 1. **Why Option B is Correct:** Onchocerciasis is caused by the nematode *Onchocerca volvulus*. While Ivermectin has been the standard of care, Moxidectin has a longer half-life (approx. 20–43 days) and is more effective at suppressing microfilarial levels in the skin for longer periods. It works by binding to glutamate-gated chloride channels, leading to hyperpolarization and paralysis of the parasite. 2. **Why Other Options are Incorrect:** * **Filariasis (Option A):** While Moxidectin is being studied for Lymphatic Filariasis (*W. bancrofti*), the specific recent FDA approval is specifically for Onchocerciasis. Diethylcarbamazine (DEC) remains a primary treatment for Filariasis. * **Hypertension (Option C):** This is a cardiovascular condition. Moxidectin has no antihypertensive properties. * **Scabies (Option D):** Ivermectin (oral) and Permethrin (topical) are the FDA-approved treatments for Scabies. Moxidectin is used off-label or in veterinary medicine for mites but lacks specific FDA approval for human scabies. **High-Yield Clinical Pearls for NEET-PG:** * **Superiority:** Moxidectin is superior to Ivermectin because it is not a substrate for P-glycoprotein pumps, meaning the parasite cannot easily pump the drug out. * **Dosage:** It is administered as a **single oral dose** (8 mg). * **Mazzotti Reaction:** Like Ivermectin, Moxidectin can trigger a Mazzotti reaction (itching, rash, fever) due to the rapid death of microfilariae, though it is generally well-tolerated.

Question 973: What is the mechanism of action of fluoroquinolones?

A. Inhibits cell wall synthesis
B. Inhibits protein synthesis
C. Inhibits DNA gyrase (Correct Answer)
D. Interferes with intermediary metabolism

Explanation: **Explanation:** Fluoroquinolones (e.g., Ciprofloxacin, Levofloxacin) are bactericidal antibiotics that primarily target bacterial DNA synthesis. They work by inhibiting two key enzymes: **DNA gyrase (Topoisomerase II)** and **Topoisomerase IV**. * **DNA Gyrase:** In Gram-negative bacteria, fluoroquinolones inhibit DNA gyrase, which is responsible for introducing negative supercoils into DNA to relieve torsional stress during replication. Inhibition leads to double-stranded DNA breaks and cell death. * **Topoisomerase IV:** In Gram-positive bacteria, the primary target is often Topoisomerase IV, which interferes with the separation (decatenation) of replicated chromosomal DNA into daughter cells. **Analysis of Incorrect Options:** * **Option A:** Inhibitors of cell wall synthesis include Beta-lactams (Penicillins, Cephalosporins) and Glycopeptides (Vancomycin). * **Option B:** Inhibitors of protein synthesis include Aminoglycosides, Tetracyclines (30S subunit), Macrolides, and Chloramphenicol (50S subunit). * **Option D:** Interference with intermediary metabolism refers to Antimetabolites like Sulfonamides and Trimethoprim, which inhibit folic acid synthesis. **High-Yield Clinical Pearls for NEET-PG:** 1. **Resistance:** Occurs via mutations in the *gyrA* or *parC* genes or through Qnr proteins (plasmid-mediated). 2. **Adverse Effects:** Most characteristic are **tendon rupture/tendonitis** (Achilles tendon) and **QT interval prolongation**. 3. **Contraindications:** Generally avoided in pregnancy and children (due to potential cartilage damage/arthropathy). 4. **Drug Interactions:** Absorption is significantly reduced when taken with antacids or divalent/trivalent cations (Al, Mg, Ca, Fe).

Question 974: Which one of the following anti-tuberculous drugs has excellent penetration into the cerebrospinal fluid?

A. Ethambutol
B. Pyrazinamide (Correct Answer)
C. Streptomycin
D. Rifampicin

Explanation: **Explanation:** The penetration of anti-tuberculous drugs into the cerebrospinal fluid (CSF) is a critical factor in treating Tuberculous Meningitis (TBM). **Pyrazinamide** is the correct answer because it is a small, highly polar molecule that achieves excellent CSF concentrations, nearly equal to its plasma levels (90–100% penetration), regardless of whether the meninges are inflamed or intact. This makes it a cornerstone in the initial phase of TBM treatment. **Analysis of Incorrect Options:** * **Ethambutol (A):** It has very poor CSF penetration (approx. 10–25%) and only crosses the blood-brain barrier significantly when the meninges are acutely inflamed. * **Streptomycin (C):** As an aminoglycoside, it is a large, polar cation that does not cross the blood-brain barrier effectively. It reaches therapeutic levels in the CSF only in the presence of severe meningeal inflammation. * **Rifampicin (D):** Despite being highly lipid-soluble, it is highly protein-bound and a substrate for P-glycoprotein efflux pumps, resulting in relatively low CSF penetration (approx. 5–20% of plasma levels). **NEET-PG High-Yield Pearls:** * **Isoniazid (INH)** and **Pyrazinamide** are the two primary first-line drugs with excellent CSF penetration. * **Fluoroquinolones** (like Levofloxacin) also show good CSF penetration and are often used in drug-resistant TBM. * For TBM, the WHO recommends a 12-month treatment regimen (2 months of HRZE followed by 10 months of HR). * **Corticosteroids** (Dexamethasone) are always added to TBM treatment to reduce perivascular inflammation and intracranial pressure.

Question 975: The characteristic toxicity of ethambutol is:

A. Hepatitis
B. Visual field defects (Correct Answer)
C. Vestibular disturbance
D. Renal damage

Explanation: **Explanation:** Ethambutol is a first-line antitubercular drug (ATT) that acts by inhibiting the enzyme **arabinosyl transferase**, thereby blocking the synthesis of the mycobacterial cell wall. **1. Why "Visual field defects" is correct:** The hallmark toxicity of ethambutol is **Retrobulbar Neuritis**. This typically manifests as a decrease in visual acuity, central scotomas (visual field defects), and **red-green color blindness**. The condition is dose-dependent (usually occurring at doses >25 mg/kg) and is generally reversible upon discontinuation of the drug. Because of this risk, patients should undergo baseline and periodic ophthalmological examinations. **2. Why other options are incorrect:** * **Hepatitis:** This is the most common side effect of other first-line ATT drugs like **Isoniazid (INH), Rifampicin, and Pyrazinamide**. Ethambutol is notably the only first-line ATT drug that is **not hepatotoxic**. * **Vestibular disturbance:** This is a classic side effect of **Streptomycin** (an aminoglycoside), which causes ototoxicity by damaging the 8th cranial nerve (vestibulocochlear nerve). * **Renal damage:** While ethambutol is excreted primarily by the kidneys and requires dose adjustment in renal failure, it is not inherently nephrotoxic. Drugs like Aminoglycosides or Amphotericin B are more typically associated with renal damage. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic:** "E" for **E**thambutol and **E**ye (Optic neuritis). * **Safe in Pregnancy:** Ethambutol is considered the safest first-line ATT during pregnancy. * **Hyperuricemia:** Ethambutol can inhibit the excretion of uric acid, occasionally leading to acute gouty arthritis (though less frequently than Pyrazinamide). * **Pediatric Caution:** It is generally avoided in children young enough that visual acuity and color vision cannot be accurately monitored (typically <6 years).

Question 976: All of the following antibiotics can be used to treat cystitis in pregnancy except?

A. Amoxycillin
B. 1st generation Cephalosporins
C. Ciprofloxacin (Correct Answer)
D. 3rd generation Cephalosporins

Explanation: **Explanation:** The correct answer is **Ciprofloxacin (Option C)**. **Why Ciprofloxacin is contraindicated:** Ciprofloxacin belongs to the **Fluoroquinolone** class of antibiotics. In pregnancy, fluoroquinolones are generally avoided (FDA Category C) because they have a high affinity for bone and cartilage. Animal studies have shown that they can cause **arthropathy** and permanent damage to the weight-bearing joints of the developing fetus (**cartilage toxicity**). Therefore, they are not first-line agents for treating uncomplicated cystitis in pregnant women. **Why the other options are incorrect:** * **Amoxycillin (Option A):** This is a penicillin derivative (FDA Category B). Penicillins are considered safe throughout pregnancy and are commonly used to treat UTIs, although resistance rates are increasing. * **1st Generation Cephalosporins (Option B):** (e.g., Cephalexin) These are FDA Category B drugs. They are highly effective against common urinary pathogens like *E. coli* and are considered safe and first-line for cystitis in pregnancy. * **3rd Generation Cephalosporins (Option D):** (e.g., Cefixime, Ceftriaxone) These are also Category B and are safe alternatives, especially for resistant cases or pyelonephritis. **NEET-PG High-Yield Pearls:** * **Safe Antibiotics in Pregnancy:** "CAMP" — **C**ephalosporins, **A**moxicillin/Ampicillin, **M**acrolides (except Erythromycin estolate), and **P**enicillins. * **Nitrofurantoin:** Safe in the 2nd trimester but avoided in the 1st trimester (risk of birth defects) and at term (risk of neonatal hemolysis/G6PD deficiency). * **Fosfomycin:** A single-dose safe alternative for cystitis in pregnancy. * **Avoid in Pregnancy:** **S**ulfonamides (Kernicterus), **A**minoglycosides (Ototoxicity), **F**luoroquinolones (Cartilage damage), **E**rythromycin estolate (Hepatotoxicity), and **T**etracyclines (Teeth discoloration/Bone hypoplasia) — Mnemonic: **"SAFE T"** (drugs that are NOT safe).

Question 977: Pyronaridine is:

A. Antimalarial (Correct Answer)
B. Anti-HIV
C. Antifungal
D. Antibacterial

Explanation: **Explanation:** **Pyronaridine** is a potent **benzanaphthyridine derivative** primarily used as an **antimalarial** agent. It was originally developed in China and is structurally related to chloroquine (4-aminoquinoline). **Why it is the correct answer:** Pyronaridine acts by inhibiting the formation of **β-haematin**, preventing the parasite from detoxifying heme into hemozoin. This leads to the accumulation of toxic heme, which destroys the malaria parasite. It is highly effective against both *Plasmodium falciparum* and *Plasmodium vivax*. In modern therapeutics, it is most commonly used in a fixed-dose combination with artesunate, known as **Pyramax®**, which is a WHO-approved **Artemisinin-based Combination Therapy (ACT)**. **Why other options are incorrect:** * **Anti-HIV:** These drugs (e.g., Tenofovir, Efavirenz) target viral enzymes like reverse transcriptase or protease. Pyronaridine has no activity against retroviruses. * **Antifungal:** Antifungals (e.g., Fluconazole, Amphotericin B) target fungal cell membranes or walls. Pyronaridine does not possess antifungal properties. * **Antibacterial:** While some antimalarials (like Doxycycline) have antibacterial properties, Pyronaridine is specific to protozoal parasites. **High-Yield Clinical Pearls for NEET-PG:** 1. **Combination Therapy:** Pyronaridine + Artesunate (Pyramax) is the first ACT to be granted a positive opinion by the EMA for treating both uncomplicated *P. falciparum* and *P. vivax*. 2. **Efficacy:** It is effective against multi-drug resistant strains of *P. falciparum*. 3. **Side Effects:** The most significant concern is a transient rise in **liver transaminases** (ALT/AST); hence, it should be avoided in patients with pre-existing liver disease. 4. **Half-life:** It has a long terminal elimination half-life (approx. 13–17 days), providing a period of post-treatment prophylaxis.

Question 978: Which oral drug is approved for the treatment of Hepatitis C?

A. Ledipsavir (Correct Answer)
B. Rimantidine
C. Telbivudine
D. Entecavir

Explanation: **Explanation:** **Correct Answer: A. Ledipasvir** Ledipasvir is a potent inhibitor of the **NS5A protein**, which is essential for Hepatitis C Virus (HCV) replication and assembly. It belongs to the class of **Direct-Acting Antivirals (DAAs)**. The management of HCV has shifted from interferon-based therapies to oral DAAs due to their high cure rates (SVR >95%) and minimal side effects [1]. Ledipasvir is most commonly used in a fixed-dose combination with Sofosbuvir (an NS5B polymerase inhibitor) for the treatment of HCV Genotype 1 [1]. **Analysis of Incorrect Options:** * **B. Rimantadine:** This is an anti-influenza medication. It acts as an **M2 ion channel blocker**, preventing the uncoating of the Influenza A virus [1]. It has no activity against HCV. * **C. Telbivudine:** This is a nucleoside analogue used specifically for **Hepatitis B (HBV)** [1]. It inhibits HBV DNA polymerase but is not effective against the RNA-based HCV. * **D. Entecavir:** A potent guanosine nucleoside analogue used as a first-line treatment for **Chronic Hepatitis B** [1]. It inhibits HBV DNA polymerase at three stages: priming, reverse transcription, and synthesis of the positive strand [1]. **High-Yield Clinical Pearls for NEET-PG:** * **HCV Drug Classes:** Remember the suffixes: **-asvir** (NS5A inhibitors like Ledipasvir), **-buvir** (NS5B inhibitors like Sofosbuvir), and **-previr** (NS3/4A protease inhibitors like Simeprevir) [1]. * **Drug of Choice:** Sofosbuvir is considered the "backbone" of modern HCV therapy [1]. * **Ribavirin:** Though used for HCV, it is associated with **hemolytic anemia** and is highly **teratogenic** (contraindicated in pregnancy) [1].

Question 979: What is the recommended treatment for Entamoeba cyst carriers?

A. Metronidazole
B. Diloxanide furoate
C. Paromomycin (Correct Answer)
D. Nitzoxanide

Explanation: The treatment of *Entamoeba histolytica* depends on whether the infection is invasive (colitis/liver abscess) or asymptomatic (cyst carrier) [2]. **Why Paromomycin is correct:** Asymptomatic cyst carriers harbor the parasite only within the intestinal lumen. To eradicate these cysts and prevent further transmission, a **luminal amebicide** is required [1]. **Paromomycin** (an aminoglycoside) is poorly absorbed from the GIT, allowing it to reach high concentrations in the gut lumen to kill cysts directly. It is currently considered the drug of choice for asymptomatic cyst passers [1]. **Analysis of Incorrect Options:** * **Metronidazole:** This is a **tissue amebicide** [2]. While it is the drug of choice for invasive intestinal amebiasis and liver abscesses, it is rapidly absorbed from the small intestine and does not reach therapeutic levels in the colon to eradicate luminal cysts [2]. * **Diloxanide furoate:** This was previously the standard luminal amebicide [1]. However, it is no longer available in many countries (including the US) and is generally considered second-line to Paromomycin due to its side effect profile (flatulence). * **Nitazoxanide:** While it has broad-spectrum antiprotozoal activity, it is not the primary recommendation for isolated cyst clearance in *E. histolytica* infections [3]. **High-Yield NEET-PG Pearls:** 1. **Sequential Therapy:** For invasive amebiasis, always follow Metronidazole (tissue amebicide) with Paromomycin (luminal amebicide) to ensure complete eradication of cysts [2]. 2. **Luminal Amebicides:** Paromomycin, Diloxanide furoate, and Iodoquinol [1]. 3. **Tissue Amebicides:** Nitroimidazoles (Metronidazole, Tinidazole), Emetine, and Chloroquine (specifically for liver abscess). 4. **Drug of Choice for Hepatic Amebiasis:** Metronidazole + Diloxanide furoate/Paromomycin.

Question 980: A patient with abdominal sepsis was started on empirical treatment with intravenous ampicillin and gentamicin. Which statement regarding the treatment of this patient is most accurate?

A. Empirical treatment of abdominal sepsis should always include a third-generation cephalosporin.
B. An antimicrobial agent active against anaerobes should be included in the antibiotic regimen. (Correct Answer)
C. The combination of ampicillin and gentamicin provides good coverage for all likely pathogens.
D. If the patient is severely allergic to ampicillin, then ceftriaxone should be used.

Explanation: ### Explanation **1. Why Option B is Correct:** Abdominal sepsis (secondary to peritonitis or abscess) is typically **polymicrobial**, involving a mixture of aerobic and anaerobic organisms. The gastrointestinal tract is a reservoir for anaerobes like *Bacteroides fragilis*. While ampicillin covers some Gram-positives and gentamicin covers Gram-negative aerobes, neither provides adequate coverage against resistant anaerobes. Therefore, adding an agent like **metronidazole** or using a carbapenem/beta-lactamase inhibitor combination is essential for therapeutic success. **2. Analysis of Incorrect Options:** * **Option A:** While third-generation cephalosporins (e.g., ceftriaxone) are common, they are not "always" required. The choice depends on local resistance patterns and the severity of the sepsis. Furthermore, they lack anaerobic coverage. * **Option C:** This combination (often called "double therapy") is insufficient because it leaves a significant "anaerobic gap." It fails to cover *B. fragilis* and many resistant Gram-negative bacilli found in the gut. * **Option D:** In cases of **severe** allergy to ampicillin (Type I hypersensitivity/anaphylaxis), there is a risk of cross-reactivity with cephalosporins (approx. 1–10%). In such scenarios, ceftriaxone should be avoided; alternatives like ciprofloxacin or aztreonam plus metronidazole are preferred. **3. Clinical Pearls for NEET-PG:** * **The "Anaerobic Gap":** Aminoglycosides (Gentamicin) have **zero** activity against anaerobes because their uptake into the bacterial cell is an oxygen-dependent process. * **Drug of Choice for Anaerobes:** Metronidazole is the gold standard for abdominal anaerobes (*B. fragilis*). For respiratory/above-diaphragm anaerobes, Clindamycin is often highlighted. * **Empirical Rule:** Always cover **Gram-positive cocci, Gram-negative bacilli, and Anaerobes** in intra-abdominal infections.

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free